Gossamer Bio, Inc.
GOSSNASDAQHealthcare● Active
$0.18
+$0.00(+2.29%)
Market Cap$42010634
P/E Ratio—
52W High$3.87
52W Low$0.163
Gossamer Bio, Inc. (GOSS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · GOSS · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $48.47M | $114.70M | $0.00M | $0.00M | $0.00M |
| Cost of Revenue | $1.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $47.47M | $114.70M | $0.00M | $0.00M | $0.00M |
| Gross Margin %(computed) | 97.93% | 100.00% | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $174.09M | $138.49M | $135.30M | $170.92M | $170.27M |
| G&A Expenses | $37.63M | $36.13M | $38.45M | $47.61M | $45.78M |
| Total Operating Expenses | $210.72M | $174.62M | $183.76M | $218.59M | $216.12M |
| Operating Income | ($163.25M) | ($59.92M) | ($183.76M) | ($218.59M) | ($216.12M) |
| Operating Margin %(computed) | -336.81% | -52.24% | — | — | — |
| Interest Income | $1.97M | $1.78M | $2.00M | $1.58M | $0.76M |
| Interest Expense | $10.99M | $11.52M | $13.51M | $13.88M | $19.44M |
| Income Before Tax | ($170.46M) | ($55.63M) | ($179.82M) | ($229.38M) | ($234.00M) |
| Income Tax Expense | ($0.09M) | $0.89M | $0.00M | $0.00M | $0.00M |
| Net Income | ($170.37M) | ($56.53M) | ($179.82M) | ($229.38M) | ($234.00M) |
| Net Margin %(computed) | -351.49% | -49.28% | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.75 | $-0.25 | $-0.80 | $-2.84 | $-3.33 |
| Wtd Avg Shares | 228.52M | 226.23M | 225.57M | 84.57M | 74.84M |
| EBITDA | ($162.25M) | ($39.97M) | ($161.92M) | ($211.07M) | ($209.40M) |
| EBITDA Margin %(computed) | -334.74% | -34.84% | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Gossamer Bio, Inc. data
About Gossamer Bio, Inc. (GOSS) Income Statement
Gossamer Bio, Inc. (GOSS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, GOSS reported revenue of $0.05B, gross profit of $0.05B (gross margin 97.93%), and net income of ($0.17B) — a net profit margin of -351.49%.
Frequently asked questions
GOSS · 4 questionsGossamer Bio, Inc. (GOSS) reported revenue of $0.05B for 2025, down 57.7% year-over-year.
GOSS revenueGOSS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08